EBX-102-02 / EnteroBiotix - LARVOL DELTA

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial (ASH 2024) - "Study Design and Methods : Fifty adult patients planned to receive allogeneic HCT for hematologic malignancies will be recruited into this phase IIa trial, and randomized 1 : 1 to receive capsulized IMT (10 capsules of EBX-102-02, a next generation, full-spectrum microbiome product derived from pooled screened donor stool; EnteroBiotix Ltd) or matched placebo at 14 days prior to initiation of HCT conditioning, and followed for up to 12 months. Secondary outcomes will include tolerability, the dynamics of gut microbiome diversity metrics and taxonomy over all timepoints assessed, as well as clinical outcomes (including burden of invasive infections, days of fever, admission to intensive care, development of graft-vs-host disease (GvHD), non-relapse mortality, survival, and GvHD-free relapse-free survival). Exploratory outcomes will include the impact of IMT upon neutrophil and platelet engraftment, and T-cell immune reconstituton and repertoire, as well as exploring..."

Clinical • P2a data • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Otorhinolaryngology • Transplantation

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL ASSESSING THE SAFETY AND EFFICACY OF EBX-102-02, AN ORAL FULL-SPECTRUM INTESTINAL MICROBIOTA PRODUCT, IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION; THE TRIUMPH TRIAL (DDW 2025) - No abstract available

Clinical • Late-breaking abstract • P2 data • Constipation • Gastroenterology • Gastrointestinal Disorder

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week 2025 (GlobeNewswire) - "EnteroBiotix Limited...today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week (DDW) 2025, to be held 3–6 May in San Diego, USA."

Late-breaking abstract • P2a data • Immunology